B-cell depletion shows therapeutic potential in relapsing–remitting MS
This article has no abstract so we have provided the first paragraph of the full text.
Evidence is accumulating to indicate that B lymphocytes have an important role in the pathogenesis of multiple sclerosis (MS). In a phase II, double-blind trial, Hauser et al. examined whether rituximab—a monoclonal antibody that depletes CD20+ B cells—could ameliorate disease activity in patients with relapsing–remitting MS.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.